Condensed Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Jun. 30, 2013	Dec. 31, 2012
Current Assets:
Cash and equivalents	$ 121,103	$ 139,698
Marketable securities	3,312	3,310
Accounts receivable, net of allowance for doubtful accounts of $239 and $228, respectively	52,379	92,169
Inventories, net	15,312	14,478
Prepaid expenses and other current assets	7,149	2,745
Tax asset	13,785	12,473
Total current assets	213,040	264,873
Property and equipment, net	2,004	2,548
Intangible assets, net	203,017	202,311
Goodwill	28,940	28,973
Other assets	13,568	7,569
TOTAL ASSETS	460,569	506,274
Current Liabilities:
Accounts payable and other accrued obligations	85,249	95,297
Accrued compensation and related expenses	4,363	4,835
Deferred revenue	2,000	12,300
Deferred development costs	3,251	856
Accrued drug development costs	12,896	15,109
Total current liabilities	107,759	128,397
Deferred revenue and other credits-less current portion	3,680	2,937
Deferred development costs, less current portion	15,400	11,377
Deferred payment contingency		2,287
Other long-term obligations	6,130	1,430
Revolving line of credit	50,000	75,000
Total liabilities	182,969	221,428
Commitments and contingencies
Stockholders' Equity:
Preferred stock	0
Common stock, $0.001 par value; 175,000,000 shares authorized; 60,284,571 and 60,026,675 shares issued and outstanding at June 30, 2013 and December 31, 2012, respectively	60	60
Additional paid-in capital	468,653	463,710
Accumulated other comprehensive gain	1,050	273
Accumulated deficit	(192,286)	(179,320)
Total stockholders' equity	277,600	284,846
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	460,569	506,274
Series B junior participating preferred stock [Member]
Stockholders' Equity:
Preferred stock
Series E convertible voting preferred stock [Member]
Stockholders' Equity:
Preferred stock	$ 123	$ 123